- Home
- GLQ vs PBYI Comparison
GLQ vs PBYI Comparison
Compare GLQ & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLQ | PBYI |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLQ | PBYI |
|---|---|---|
| Price | $7.62 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 65.5K | ★ 398.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.11% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.56 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $2.58 |
| 52 Week High | $6.54 | $6.12 |
Technical Indicators
Market Signals| Indicator | GLQ | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 64.05 |
| Support Level | $7.40 | $5.51 |
| Resistance Level | $7.74 | $5.73 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 60.59 | 93.61 |
Price Performance
Historical ComparisonAbout GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.